Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized phase II study of FOLFIRI with or without cetuximab in elderly patients with advanced colorectal cancer
2012-000477-23Phase 2Active
- Sponsor
- Azienda Ospedaliero-Universitaria delle Marche
- Start
- Apr 2012
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of cetuximab, irinotecan, fluorouracil and folinic acid in colorectal cancer (CRC) and colorectal adenocarcinoma (2 arms), sponsored by Azienda Ospedaliero-Universitaria delle Marche. Primary endpoint: Progression-free at 6 months. Started Apr 2012; status: active.
02
Drugs
cetuximabirinotecanfluorouracilfolinic acid
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinoma
Beyond the preview
Go deeper on 2012-000477-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000477-23.